Should I buy or sell Immix Biopharma stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immix Biopharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMMX shares. View IMMX analyst ratings or view top-rated stocks .

What is Immix Biopharma's stock price target for 2024?

1 analysts have issued twelve-month price objectives for Immix Biopharma's stock. Their IMMX share price targets range from $14.00 to $14.00. On average, they anticipate the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 539.3% from the stock's current price. View analysts price targets for IMMX or view top-rated stocks among Wall Street analysts .

How have IMMX shares performed in 2024?

Immix Biopharma's stock was trading at $6.92 at the beginning of 2024. Since then, IMMX stock has decreased by 68.4% and is now trading at $2.19. View the best growth stocks for 2024 here .

When is Immix Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our IMMX earnings forecast .

When did Immix Biopharma IPO?

Immix Biopharma (IMMX) raised $23 million in an initial public offering on Thursday, December 16th 2021. The company issued 4,200,000 shares at a price of $5.00-$6.00 per share.

How do I buy shares of Immix Biopharma?

Shares of IMMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:IMMX

Immix Biopharma (IMMX) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free IMMX Stock Alerts

$2.19

-0.02 (-0.90%)

(As of 04/19/2024 ET)

Compare

Today's Range: $2.18
▼
$2.33
50-Day Range: $2.19
▼
$3.70
52-Week Range: $1.40
▼
$7.75

Volume: 63,953 shs
Average Volume: 263,870 shs
Market Capitalization: $57.82 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.00

Get Immix Biopharma alerts:

Immix Biopharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 539.3% Upside
$14.00 Price Target
Short Interest: Healthy
2.81% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.34
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.91) to ($0.94) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.62 out of 5 stars

Medical Sector

656th out of 911 stocks

Pharmaceutical Preparations Industry

283rd out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
Immix Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Immix Biopharma has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.81% of the float of Immix Biopharma has been sold short.
Short Interest Ratio / Days to Cover
Immix Biopharma has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Immix Biopharma has recently increased by 22.80%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Immix Biopharma does not currently pay a dividend.
Dividend Growth
Immix Biopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IMMX.

1.9

News and Social Media Coverage

News Sentiment
Immix Biopharma has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Immix Biopharma this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for IMMX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Immix Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Immix Biopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
55.90% of the stock of Immix Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 11.26% of the stock of Immix Biopharma is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Immix Biopharma are expected to decrease in the coming year, from ($0.91) to ($0.94) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Immix Biopharma is -2.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Immix Biopharma is -2.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Immix Biopharma has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Immix Biopharma Stock (NASDAQ:IMMX)

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

IMMX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IMMX Stock News Headlines

April 18, 2024 | finance.yahoo.com

Immix Biopharma, Inc. (IMMX)

April 18, 2024 | finanznachrichten.de

Immix Biopharma, Inc.: Immix Biopharma on Track to Dose NXC-201 Patients in United States

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

April 18, 2024 | globenewswire.com

Immix Biopharma on Track to Dose NXC-201 Patients in United States

April 15, 2024 | globenewswire.com

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

April 2, 2024 | investorplace.com

IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023

March 20, 2024 | globenewswire.com

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

March 7, 2024 | stockhouse.com

Immix Biopharma Announces "Be Proactive in AL" AL Amyloidosis Awareness Initiative

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 5, 2024 | globenewswire.com

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

February 24, 2024 | msn.com

Immix Biopharma (IMMX) Price Target Increased by 27.27% to 14.28

February 22, 2024 | finance.yahoo.com

IMMX Apr 2024 7.500 call

February 21, 2024 | finanznachrichten.de

Immix Biopharma, Inc.: Immix Biopharma 12 Month Review Progress Update

February 21, 2024 | markets.businessinsider.com

Immix Biopharma 12 Month Review Progress Update

February 21, 2024 | finance.yahoo.com

Immix Biopharma 12 Month Review Progress Update

February 21, 2024 | globenewswire.com

Immix Biopharma 12 Month Review Progress Update

February 13, 2024 | finance.yahoo.com

IMMX Aug 2024 2.500 call

February 8, 2024 | finance.yahoo.com

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

February 8, 2024 | finanznachrichten.de

Immix Biopharma, Inc.: Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

February 7, 2024 | markets.businessinsider.com

Immix Biopharma Signs Definitive $15M Titan Partnership Deal

February 7, 2024 | finance.yahoo.com

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

February 6, 2024 | msn.com

Immix Biopharma Suspends Stock Offering Pending New Prospectus

February 5, 2024 | finance.yahoo.com

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

February 5, 2024 | finance.yahoo.com

Immix Biopharma Announces Proposed Public Offering of Common Stock

January 24, 2024 | markets.businessinsider.com

Immix Biopharma Reveals FDA Labeling Change Notification For CAR-T Products

January 24, 2024 | finanznachrichten.de

Immix Biopharma, Inc.: Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

January 24, 2024 | finance.yahoo.com

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

See More Headlines

Receive IMMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:IMMX
CUSIP: N/A
CIK: 1873835
Web: www.immixbio.com
Phone: 310-651-8041
Fax: N/A
Employees: 14
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $14.00
High Stock Price Target: $14.00
Low Stock Price Target: $14.00
Potential Upside/Downside: +539.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-15,430,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -101.56%
Return on Assets: -86.70%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.32
Quick Ratio: 5.32

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.81 per share
Price / Book: 2.70

Miscellaneous

Outstanding Shares: 26,400,000
Free Float: 11,641,000
Market Cap: $57.82 million
Optionable: Optionable
Beta: 0.05

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Ilya Rachman M.B.A. (Age 51)
M.D., MBA, Ph.D., Co-Founder, CEO & Chairman
Comp: $637.5k
Mr. Gabriel Morris B.A. (Age 37)
CFO & Director
Comp: $637.5k
Mr. Sean Senn J.D.
M.B.A., M.Sc., MBA, MSc, Co-Founder
Dr. Vladimir P. Torchilin D.Sc. (Age 77)
MSE, Ph.D., Scientific Co-Founder
Mr. Ben H. Lyon J.D.
Executive VP & General Counsel
Dr. Graham Ross FFPM (Age 64)
M.D., Chief Medical Officer & Head of Clinical Development
Mr. Nandan Oza B.S. (Age 62)
Head of Chemistry, Manufacturing & Control
Dr. David Marks
Chief Medical Officer of Cell Therapy
Mr. Gerhard Bauer
Head of Cell Thearpy Manufacturing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IMMX Stock Analysis - Frequently Asked Questions

Should I buy or sell Immix Biopharma stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immix Biopharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMMX shares.
View IMMX analyst ratings or view top-rated stocks.
What is Immix Biopharma's stock price target for 2024?: 1 analysts have issued twelve-month price objectives for Immix Biopharma's stock. Their IMMX share price targets range from $14.00 to $14.00. On average, they anticipate the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 539.3% from the stock's current price.
View analysts price targets for IMMX or view top-rated stocks among Wall Street analysts.
How have IMMX shares performed in 2024?: Immix Biopharma's stock was trading at $6.92 at the beginning of 2024. Since then, IMMX stock has decreased by 68.4% and is now trading at $2.19.
View the best growth stocks for 2024 here.
When is Immix Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our IMMX earnings forecast.

When did Immix Biopharma IPO?: Immix Biopharma (IMMX) raised $23 million in an initial public offering on Thursday, December 16th 2021. The company issued 4,200,000 shares at a price of $5.00-$6.00 per share.
How do I buy shares of Immix Biopharma?: Shares of IMMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMMX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Immix Biopharma (IMMX) Stock Price, News & Analysis

Immix Biopharma MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Immix Biopharma Stock (NASDAQ:IMMX)

IMMX Stock Price History

IMMX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

IMMX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™